Diagnostics & Research · Menlo Park, California, United States
$95.03
-0.64% (-$0.61)2026-08-21
Smart-Money SignalDistribution · 36/100— Insiders are net sellers over 90 days (-$29.0M, 131 sales vs 26 buys)
Revenue$109.4M
Net Income$8.1M
EPS$0.48
Gross Margin70.5%
Market Cap$1.1B
Price Performance
Historical data including institutional events
Company Profile
O
Oguzhan Atay
CEO & Executive Director
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision.
BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.